## UC Irvine UC Irvine Previously Published Works

## Title

Emotion regulation therapy for cancer caregivers—an open trial of a mechanism-targeted approach to addressing caregiver distress

**Permalink** https://escholarship.org/uc/item/8b86b222

**Journal** Translational Behavioral Medicine, 10(2)

**ISSN** 1869-6716

## Authors

Applebaum, Allison J Panjwani, Aliza A Buda, Kara <u>et al.</u>

Publication Date 2020-05-20

## DOI

10.1093/tbm/iby104

Peer reviewed

# TBM

# Emotion regulation therapy for cancer caregivers—an open trial of a mechanism-targeted approach to addressing caregiver distress

Allison J. Applebaum,<sup>1</sup> Aliza A. Panjwani,<sup>2</sup> Kara Buda,<sup>1</sup> Mia S. O'Toole,<sup>3</sup> Michael A. Hoyt,<sup>2</sup> Adam Garcia,<sup>1</sup> David M. Fresco,<sup>4</sup> Douglas S. Mennin<sup>5</sup>

<sup>1</sup>Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10022 <sup>2</sup>Department of Psychology, Hunter

College, New York, NY 10065 <sup>3</sup>Department of Psychology &

Behavioral Sciences, Aarhus, Denmark, 8000

<sup>4</sup>Department of Psychological Sciences, Kent State University, Kent. OH 44242

<sup>5</sup>Department of Psychology, Teachers College, Columbia, New York, NY 10027

#### Correspondence to: Allison J. Applebaum, applebaa@mskcc. org

Cite this as: *TBM* 2020;10:413–422 doi: 10.1093/tbm/iby104

© Society of Behavioral Medicine 2018. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. Informal caregivers (ICs) are integral to care provided to patients facing life-threatening or incurable illnesses. This responsibility causes considerable burden, as approximately one half of ICs report clinically significant symptoms of depression and/or anxiety that persist when left untreated. Psychosocial interventions containing efficacious treatment principles (e.g., cognitive behavior therapy [CBT]) show disappointing results in reducing anxiety and depression in ICs. This may reflect failure of these interventions to specifically target crucial mechanisms underlying the central feature of distress caused by the patient's illness-notably, perseverative negative thinking (PNT). Emotion Regulation Therapy (ERT) is an efficacious CBT developed to explicitly target mechanisms underlying PNT and the emotional concomitants that arise in response to stressful situations. This open trial was conducted to evaluate the acceptability and initial efficacy of ERT adapted to the experience of cancer ICs (ERT-C). Thirty-one ICs provided informed consent and completed eight weekly individual sessions of ERT-C. Participants completed self-report measures of depression and anxiety symptoms, PNT, emotion regulation deficits, and caregiver burden before and after treatment. ERT-C was well tolerated as indicated by 22 treatment completers and feedback provided in exit interviews. ICs demonstrated reduced depression and anxiety symptoms, PNT, and emotion regulation deficits with moderate to large effect sizes (Hedge's g range: 0.36-0.92). Notably, caregiver burden was not reduced but ICs expressed more ability to confront caregiving-related challenges. Findings offer promising but preliminary support for ERT-C as a conceptual model and treatment modality for distressed cancer ICs.

#### Keywords

Abstract

Informal caregivers, Cancer, Distress, Emotion regulation therapy, Perseverative negative thinking

#### INTRODUCTION

Informal caregivers (ICs) are relatives, partners, or friends who have a significant relationship with and provide assistance (i.e., physical, emotional) to a patient with often life-threatening and/or incurable illnesses [1]. In 2016, over 65 million people in the USA served as ICs for medically ill relatives, including nearly 5 million patients with cancer [1]. This number may reflect the rising cost of health care, which places the responsibility of caring for the chronically medically ill on ICs [2]. Consequently, attention to the unique burden of ICs is needed, not only for their benefit, but also for the patient

#### Implications

**Practice:** Describing Emotion Regulation Therapy for Cancer Caregivers (ERT-C) will inform practitioners considering how to best support cancer caregivers experiencing significant distress as a result of the caregiving role.

**Policy:** The development of targeted, efficacious and time-limited support programs are needed to address the multiple concerns of a large number of caregivers.

**Research:** Further research is needed to establish the efficacy of ERT-C using a randomized controlled trial (RCT) design. Longer follow-up periods and larger sample sizes would allow for rich assessment of psychological, biological and physiological mechanisms underlying the changes resulting from ERT-C.

whose care is highly impacted by their IC's well-being [3, 4]. Indeed, attending to the psychosocial needs of ICs is increasingly seen as crucial element of comprehensive care for patients with cancer.

The extant literature documents high levels of psychological distress among cancer ICs, among whom over half report clinically significant symptoms of depression and/or anxiety [5–10]. When examined prospectively, rates of anxiety and depression among cancer ICs increase over time if left untreated [11]. Chronic distress associated with caregiving increases risk for medical complications among ICs, including poor immune functioning, cardiovascular disease, and sleep difficulties [12, 13]. The impact of distress may also contribute to dysregulation in biological processes, such as diurnal cortisol rhythm [14] and pro-inflammatory cytokine activation [15].

Distress is commonly defined as prolonged internal suffering that can range from self-focused processing of negative emotions and stressors, to highly intensely aversive and prolonged processing of emotional states [16]. Distress can be brought on by attention to cues of threat and reward related to some actual or perceived stressful situation and is, subsequently, worsened and prolonged when individuals engage in perseverative negative thinking (PNT) [17], such as worry, depressive rumination, and self-criticism. PNT refers to mental activity that arises when individuals experience a discrepancy between their current emotional/motivational state and a representation of the future (i.e., planning), the past (i.e., failures/losses), or an idealized self (i.e., self-criticism).

Although the term PNT is not specifically used in the caregiving literature, the scope of what PNT references is well documented among ICs. Beyond the news that a loved one has received a cancer diagnosis, providing care for a loved one is fundamentally characterized by conflicting emotional and motivational states. Cancer ICs may concurrently wish for a happy future with their loved ones while engaging in anticipatory bereavement or fear their loved one's passing while appreciating the relief that may come with that transition. This state of emotional and motivational conflict is often ongoing, unrelenting, and likely occupying the minds of ICs. Findings consistently indicate that among cancer ICs, PNT accounts for a large portion of their overall distress [18-20] and prevents them from flexibly attending to salient cues in the environment and to emotions that arise in a contextually appropriate manner [21-23].

For example, previous research on cancer ICs has demonstrated that repetitive negative thinking may mediate the relationship between burden and depressive symptoms [24] and that ICs reported higher levels of distress caused by rumination compared to controls [25]. A study conducted by Gaugler, Eppinger, King, Sandberg, and Regine (2013) on coping strategies in cancer ICs found that those who experienced more problems coping with cancer care reported greater feelings of emotional exhaustion and fatigue, were more likely to feel trapped in their care responsibilities, and experienced greater feelings of guilt. Further, this study found that ICs who employed more negative expectation coping strategies (including worry, expecting the worst, and getting nervous) were more likely to report somatic and subjective anxiety and depressive symptoms [17]. Consequently, the distress experienced by cancer ICs is worsened and, in turn, may interfere with the care they provide to their loved one.

In our systematic review [23] of 49 psychosocial intervention studies for ICs, we highlighted the benefits of individual supportive interventions (versus with patients present or in group formats) and structured, manualized treatment (e.g., cognitive behavior therapy [CBT], interpersonal psychotherapy) to improve various aspects of psychosocial well-being for ICs. Such interventions also improved IC enrollment and retention, likely due to their sensitivity to the many demands of caregiving that historically prevent ICs from engaging in psychosocial support [26]. However, our subsequent meta-analytic results revealed that although CBT is one of the most well-researched and efficacious psychosocial treatments for mood and anxiety disorders [27, 28], it has consistently failed to extend that efficacy into specifically reducing the anxiety and depression in ICs. Indeed, our meta-analysis found a small and significant effect of CBTs for ICs directly following treatment (Hedge's g = 0.08, p = .014), which disappeared when randomized controlled trials (RCTs) were evaluated alone (g = 0.04, p = .200) [29]. This finding may be due, in part, to a lack of targeted focus on the mechanisms underlying the central feature of distress caused by the patient's illness-notably, PNT. As such, psychosocial interventions that more focally conceptualize and target the distress of ICs seems warranted.

#### **Emotion Regulation Therapy**

Emotion Regulation Therapy (ERT) is mechanism-targeted, experientially-oriented CBT that integrates traditional and contemporary CBT [30] and emotion-focused therapies [31]. Rooted in a framework that draws from basic and translational affect science, ERT was developed to improve treatment for conditions in which PNT is considered a crucial maintaining factor, such as in the case of caregiver distress.

As compared to more traditional CBTs, ERT is more explicit in the delineation of the functional role of emotions and underlying motivations ([32, 33]). Specifically, ERT promotes (i) increased emotional and behavioral awareness, (ii), emotion regulatory capacities, and (iii) engagement of new contextual learning repertoires [32]. Initially, ERT centers on developing mindfulness skills to encourage intentional, flexible responding to challenging emotions, such as anxiety, sadness, and anger. In particular, ERT utilizes mindful emotion regulation skills intended to improve attention regulation (e.g., shifting and sustaining attention on difficult emotional stimuli) and meta-cognitive regulation skills (e.g., decentering or the ability to observe items that arise in the mind with distance and perspective and reappraisal or the ability to reinterpret the meaning of events to change the emotional trajectory). Instead of responding reactively to intense emotional situations such as with criticism, rumination, or worry, patients are taught to respond "counteractively" by applying the mindfulness skills when they first notice the arising of difficult emotions and their underlying motivational cues. After learning the skills, ERT patients engage conflicting emotional/ motivational states via imaginal exposure to feared possibilities, and dialogue tasks to encourage behavioral activation of desired affective states. The goal is to promote living "proactively," assisting patients in taking actions consistent with their values.

ERT has demonstrated considerable preliminary efficacy as well as initial support for the role of regulatory mechanisms using both behavioral and neural indices associated with ERT clinical outcomes (e.g., [34, 35]). In an open and randomized controlled trial of adults diagnosed with generalized anxiety, with or without co-occurring depression, patients evidenced gains on measures of PNT (e.g., worry, rumination) and reductions in trait anxiety, depressive symptoms, and quality of life [16, 33]. Similarly, a recent open trial demonstrated efficacy for a slightly shortened ERT format among a diverse sample of young adults diagnosed with an anxiety or mood disorder, with strong effect sizes for changes pre-to-post treatment in worry, rumination, generalized anxiety, anhedonic depression, clinician-rated severity of generalized anxiety disorder (GAD) and major depressive disorder (MDD), social disability, and quality of life (OOL) [35].

In its original format, ERT is delivered as 16 weekly in-person sessions. In ERT-C, we consolidated the treatment into eight sessions that were scheduled at times convenient to ICs to be sensitive to caregiving demands and reported barriers to psychosocial service use [36-38]. Given these considerations, the mindfulness skills and dialogue task were adapted to be optimally applicable to the cancer caregiving context, though the goals of the exercises remained the same. The separate modules train ICs in: (i) cue detection and delineation of problematic motivational (i.e., threat and/or loss-based) and regulatory (i.e., worry, rumination, self-criticism, reassurance seeking, avoidance/withdrawal, and/or compulsive behaviors) responses; (ii) attentional skills to increase the ability to broaden, shift, and sustain attention when distressed; (iii) meta-cognitive skills to more effectively distance and reframe emotional thoughts; and (iv) improving the ability to more flexibly engage contexts that are rewarding even when accompanied by loss/threat. To increase relatability and relevance for the cancer IC population, each module was updated to contain IC-specific examples with challenges common to the cancer caregiving context.

Given the high levels of PNT detected in ICs, combined with the preliminary efficacy of ERT, the purpose of this study was to evaluate the feasibility, acceptability, and preliminary effects of ERT-C in a sample of cancer ICs who were experiencing elevated distress in the presence of PNT. We assessed a broad array of clinical and theoretically motivated self-report measures to examine the potential impact of ERT-C.

#### **METHOD**

#### Participants

Participants were recruited from Memorial Sloan Kettering Cancer Center (MSK) through in-person at clinic appointments, via physician referral (i.e., physicians who encountered ICs notified study staff), and through informational flyers that were posted in clinic waiting rooms. Participants were: (i) at least 18 years of age; (ii) a self-reported current caregiver to a patient with any site/stage of cancer; (iii) able to read and understand English; and (iv) able to provide informed consent. Participants were excluded if they reported any of the following: (i) lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder; (ii) presence of disorder that compromises comprehension of assessments or informed consent information (e.g., Alzheimer's disease, dementia); (iii) regular smoker (daily use); (iv) heavy drinker (regularly having more than 14 alcoholic beverages per week); and (v) engaging in night shift work. While not presented here, data collection also included psychoneuroimmunological (PNI) indicators of distress, including circulating biomarkers (via blood samples) and salivary cortisol. It was due to these indicators that the latter three exclusion criteria are listed, as these can confound PNI outcomes. Additionally, participants needed to meet cutoff criteria on the Distress Thermometer measure (DT;  $\geq$ 4) [39] and either elevated rumination (Brooding Subscale of the Rumination Response Scale; ≥12) [40] or worry (Brief Penn State Worry Ouestionnaire; >15) [41].

#### Procedure

Thirty-two individuals met this criterion for distress, provided informed consent, and were enrolled in this trial. Quantitative assessments were completed at baseline (T1) and after completion of ERT-C (T2). Additionally, a subset of treatment completers (n = 10) completed semistructured interviews that explored how ERT-C attended to their unique experience of worry and rumination and ways in which ERT-C could more specifically target the emotion regulation needs of cancer ICs. We limited these interviews to 10 participants based on qualitative methodological standards for reaching data saturation [42]. By the 10th interview, we reached data saturation of themes based on participant reported experiences.

#### Emotion Regulation Therapy for Cancer Caregivers

ERT-C is a manualized treatment for ICs and consists of eight weekly hour-long sessions delivered in person. Homework exercises are assigned after each session to facilitate the learning and consolidation of ERT-C skills. The session topics (and specific skills taught) are as follows: Session 1-Introduction to ERT-C (Cue detection/self-monitoring); Session 2-Attention Regulation (Orienting and Allowing); Session 3-Meta-Cognitive Emotion Regulation Courageous/Compassionate (Distancing and Session 4-On-the-Spot Regulatory Reframing); Responding; Sessions 5-7-Being Proactive (imaginal and in vivo exposure to desired and valued

actions); and Session 8–Consolidating Gains and Relapse Prevention.

Therapists were extensively trained in the rationale and principles of ERT-C as well as implementation in the cancer-related caregiving context. Training also entailed reviewing videos of prior therapy patients (i.e., patients in other trials who had received ERT for chronic anxiety and depression and consented to have video recordings of their sessions shared for training purposes), as well as role-plays focused on delivery of the core skills to be imparted and the setup and delivery of in-session exposure/behavioral activation tasks. Following training, therapists received weekly telephone and/ or face-to-face supervision with prior review of audio-recorded sessions.

#### Quantitative assessments

#### Demographic form

Demographic information including gender, age, race, ethnicity, education, employment, religious affiliation, and marital status was collected at baseline. Information regarding whether the patient and IC cohabitate, patient-IC relationship type (i.e., spouse, parent, etc.), length of caregiving (i.e., years caregiving, hours per week spent providing care), and patient-related information (i.e., site and stage of disease) was also collected.

#### Distress Thermometer

The DT [39] is a single-item visual analog scale used to screen cancer patients for the presence of psychological distress with a 0–10 range. The National Cancer Center Network (NCCN) Clinical Practice Guidelines for Distress Management recommend use of the DT, along with a 34-item problem checklist [43, 44]. An extensive research literature has documented the utility of the DT as a screening tool for oncology settings, and has identified a cutoff of 4 or greater for identifying clinically significant psychological distress [45, 46].

Perseverative Negative Thinking was assessed by two measures. Rumination was measured with the Ruminative Response Scale (RRS) [22] using the Brooding Subscale, which is composed of five items assessing the tendency toward repetitive, negative thinking (e.g., "I think about a recent situation, wishing it could have gone better"). Participants rate the frequency with which they use ruminative strategies using a 4-point Likert scale ranging from 1 (never) to 4 (always), and higher scores reflect higher frequencies of brooding. The RRS has demonstrated high internal consistency  $(\alpha = 0.89)$  [22]. Worry was measured by the *Penn State* Worry Questionnaire (PSWQ) [47], a widely used 16-item measure of trait worry with scores ranging from 16 to 80 with higher scores indicating more pathological worry. The PSWQ has demonstrated high internal consistency ( $\alpha = 0.93$ ) [47].

Caregiver Burden was assessed by the Caregiver Reaction Assessment (CRA), a 24-item self-report measure that assesses multiple dimensions of caregiver burden, including self-esteem, family support, finances, schedule, and health. Items are rated on a 5-point Likert-type scale. The CRA has been used widely in studies with ICs of cancer patients [48–51], and has demonstrated good internal consistency (range  $\alpha = 0.73-0.84$ ) and construct validity [48, 52].

Depression and Anxiety was assessed using the Hospital Anxiety and Depression Scale (HADS) [53], a 14-item selfrated questionnaire with separate (7-item) depression and anxiety subscales. The HADS has been well tested as a measure of overall psychological distress in cancer populations, and has demonstrated good internal consistency ( $\alpha = 0.83$ ) [54] and strong test-retest reliability and validity [55].

Emotion Regulation was assessed using two measures. The Difficulties in Emotion Regulation Scale (DERS) [56] is a 36-item measure comprised of six subscale scores measuring difficulties with aspects of emotion regulation, including: acceptance of emotions, ability to engage in goal-directed behavior when distressed, impulse control, awareness of emotions, access to strategies for regulation, and clarity of emotions. The DERS has demonstrated good internal consistency ( $\alpha = 0.93$ ). The *Five Facet* Mindfulness Questionnaire (FFMQ) [57] is a 39-item self-report measure comprised of five factors (observing, describing, acting with awareness, nonjudging of internal experience, and nonreactivity to internal experience). The FFMQ has demonstrated good internal consistency (range  $\alpha = 0.86-0.95$ ) [58].

#### Semistructured interview

Research staff members who did not serve as ERT-C therapists used a scripted interview guide that the research team developed iteratively. Its content and wording were reviewed by an IC, a qualitative methods expert, and a psychologist with experience working with ICs.

Study procedures were reviewed by the Memorial Sloan Kettering Institutional Review Board (approval number 15-219) and all participants provided informed consent before enrollment. The Clinical Trial Registration Number for this study is NCT02697357.

#### Statistical Analysis

Descriptive statistics for demographic variables and measure scores are produced for all participants at pre-ERT assessment. To assess the effect of ERT-C on the outcomes described above, means and 95% confidence intervals are reported for measure scores for both time points as well as for the change scores of participants who completed both assessments. Noting the sample size limitations, we calculated Hedge's g statistic to estimate effect size across measures. Like Cohen's (1992) d, common effect size conventions for Hedge's g are small = 0.20, medium = 0.50, large = 0.80 [57]. However, Hedge's g is preferable to Cohen's d especially in small samples as the effect size estimates are more reliably reproduced in larger samples [59].

Qualitative methods were employed to evaluate participant responses to the semistructured interview. Two study team members who did not conduct the interview were involved in the transcription and interpretive process. One member transcribed the interview, and the transcription was subsequently verified for fidelity by the other. The interview transcripts were then analyzed with a targeted inductive procedure of qualitative thematic text analysis. This involved thorough reading and review of transcripts by two members of the study team; synthesizing key conceptual findings from each transcript; identifying key conceptual findings across all transcripts; and generating descriptive and interpretive themes for the entire data set [60–63].

#### RESULTS

Demographic characteristics of participants are presented in Table 1. Participants who completed the baseline assessment (N = 31) were predominantly female (87%), White (77%) and married/partnered (81%), and on average 54 years old. The majority (61%) were the partner of the patient for whom they were providing care, whereas 19% identified as children and 16% as parents of patients with cancer. Three quarters (71%) of participants had provided care for their loved one since the time of diagnosis, which ranged from 3 to 83 months (average duration of caregiving was 27.6 months). More than half (58.1%) of participants reported annual incomes greater than \$75,000 and nearly all had attained a college degree or postgraduate/professional experience (93.6%).

#### Feasibility and Acceptability

There was moderate attrition from this pilot trial; 31% of enrolled participants did not complete all ERT-C sessions and 37.5% of participants did not complete the entire study (including the T2 assessment). Participant baseline characteristics and instrument scores did not meaningfully differ between attrition strata, with the exception of caregiver burden (CRA total scores for completers and non-completers at T1 were 76.90 and 84.64 [p = .034]). In Fig. 1, we present the Trend data outlining participation in this trial.

Two key themes emerged from the semistructured interviews regarding feasibility and acceptability: ERT-C content and ERT-C delivery. In terms of ERT-C content, conceptual findings included feedback regarding the meditation exercises, the potential for ICs' loved ones to be involved in the therapy, and learning new concepts. Specifically, in terms of content, more than half of the participants interviewed liked the meditation scripts/audios and used them throughout participation and after the conclusion of treatment. The majority of ICs interviewed appreciated the delivery of sessions individually and the opportunity to have space to process their unique experience, but also felt that it would be beneficial for the patient to join in at least one session so that they could address skills-building together. While almost all ICs interviewed found session material on being courageous and compassionate helpful, about 50% stated that talking about these concepts was much easier than putting them into practice, and that engaging in self-care was not something to which they were accustomed. For example, one participant stated, "I have plenty of physical courage, but do I have moral courage? That's harder, it's a question I ask myself often. Do I have the courage to face myself? Do I have sufficient compassion for myself to actually insist on taking care of myself?"

In terms of ERT-C delivery, conceptual findings included feedback regarding homework assignments, the timing/frequency of sessions, and the delivery of ERT-C in person. Specifically, ICs found the weekly homework exercises helpful and not burdensome to complete, and similarly found that engaging in weekly 1-hr sessions was feasible, and even suggested the possibility of additional sessions to allow for further refinement of skills. Moreover, while two participants stated that sessions conducted via telehealth (e.g., telephone, Skype) modalities would allow for greater flexibility with scheduling, all 10 ICs reported preferring and appreciating the face-to-face interaction and the benefit of the felt experience of being witnessed in person.

#### Preliminary effects

In Table 2, we present the effect of ERT-C on overall and subscale scores.

#### Depression and anxiety symptoms

Patients receiving ERT-C evidenced substantial reductions in HADS depression, anxiety, and total scores with effect sizes reaching or surpassing medium effects.

#### Perseverative negative thinking

Patients receiving ERT-C evidenced meaningful reductions on both measures of negative self-referentiality with effect sizes approaching medium effects.

#### Emotion regulation

Patients receiving ERT-C evidenced strong reductions in emotion regulation deficits as well as gains in trait mindfulness with effect sizes approaching or exceeding conventions for large effects.

#### Caregiver burden

Patients receiving ERT-C endorsed a slight, nonsignificant increase in feelings of burden from T1 to T2. Although pre-ERT-C and post-ERT-C means

Maile     Frequency (%)       Gender     4 (129)       Maile     4 (129)       Fernale     27 (87.1%)       Age     54.45 (11.14)       Receptinicity     1 (3.2)       AsianPacific Islander     1 (3.2)       AsianPacific Islander     2 (6.5)       Other     2 (6.5)       Other     1 (3.2)       Stanport     2 (6.5)       Income     2 (6.5)       Stanport     2 (6.5)       Income     1 (3.2)       Stanport     1 (3.2)       Stanport     5 (16.1)       Advance     2 (16.1)       Vocational school resone college     2 (16.1)       Vocational school resone college     3 (9.7%)       Single/never maried     3 (9.7%)       Single/never maried     3 (9.7%)       Marter(styartmered	Table 1   Participant characteristics		
Gender     4 (12.9)       Image     4 (12.9)       Fernale     27 (87.18)       Regeltmicity	Characteristic	Mean ( <i>SD</i> )	Frequency (%)
Male     4 (12.9)       Female     27 (87.13)       Age     54.45 (11.14)       Bace/Ethicity     1 (3.2)       Asian/Pacific Islander     1 (3.2)       Caucasian/White     24 (67.74)       Latino/Hispanic     2 (6.5)       Differ     1 (3.2)       Two or more races     2 (6.5)       Income     1 (3.2)       S20.000 to 519.999     1 (3.2)       S20.000 to 539.999     1 (3.2)       S20.000 to 539.999     1 (3.2)       S20.000 to 539.999     1 (3.2)       S75.000 or more     18 (68.1)       Professional or graduate school experience     10 (32.3)       Professional or graduate school experience     10 (32.3)       Professional or graduate school experience     10 (32.3)       Maried/partnered     2 (60.6%)       Divorced/separated     3 (9.7%)       Relationship to patient     2       Parent     5 (16.1)       Speck/partner     10 (61.3)       Oversel/separated     3 (9.7%)       Siling     1 (3.2)       Corespecting the time	Gender		
Fernale     27 (87.1%)       Age     54.45 (11.14)       Racyelthricity     Atrian American/Black     1 (3.2)       Asan/Pacific Islander     1 (3.2)       Caucaslar/White     24 (77.4)       Latino/Hispanic     2 (6.5)       Other     1 (3.2)       Two or more races     2 (6.5)       Income     1 (3.2)       510.000 to 519.999     1 (3.2)       540.000 to 519.999     1 (3.2)       550.00 to 539.999     1 (3.2)       College degree     10 (32.3)       Prefers not onswer     5 (16.1)       Education level     10 (32.3)       College degree     10 (32.3)       Verofessional or graduate school experience     1 (3.2)       Variandaritered     25 (80.6%)       Divorcad/separated     3 (9.7%)       Single/never maried     3 (9.7%)       Single/never maried for since diagnosis     2 (19.4)       Yes- on and or fince diagnosis     6 (19.4) <td>Male</td> <td></td> <td>4 (12.9)</td>	Male		4 (12.9)
Age     54.45 (11.14)       Race/ethnicity     1(3.2)       Artican American/Black     1 (3.2)       Caucasian/White     24 (67.74)       Latino/Hispanic     2 (6.5)       Dther     1 (3.2)       Two or more races     2 (6.5)       Income     2 (6.5)       Stopool to 519,999     1 (3.2)       S20.000 to 539,999     1 (3.2)       S75.000 or more     18 (58.1)       Prefer not to answer     5 (16.1)       S75.000 or more     18 (58.1)       Prefer not to answer     5 (16.1)       College degree     10 (32.3)       Protessional or graduate school experience     10 (61.3)       Vocational school or some college     2 (6.5)       Relationship status     2       Marriett/partnered     3 (9.7%)       Diorece/Separated     3 (9.7%)       Yes-constantly since diagnosis     2 (11.1)       Stingle/never married     3 (9.7%)       Ves-constantly since diagnosis     2 (19.4)       Yes-constantly since diagnosis     5 (16.1)       No     8 (25.8)	Female		27 (87.1%)
Bace/ethnicity     African American/Black     1 (3.2)       Aslan/Pacific Islander     1 (3.2)       Aslan/Pacific Islander     1 (3.2)       Latino/Hispanic     2 (6.5)       Other     1 (3.2)       Income     2 (6.5)       S10,000 to \$19,999     1 (3.2)       S40,000 to \$74,999     5 (16.1)       55,000 to \$74,999     5 (16.1)       55,000 to \$74,999     5 (16.1)       55,000 to \$89,999     1 (3.2)       S75,000 to s0 \$9,999     1 (3.2)       College degree     10 (32.3)       Professional or gaduate school experience     10 (61.3)       Spinge/never maried     3 (9.7%)       Brain mered     2 (80.6%)	Age	54.45 (11.14)	
African American/Black     1 (3.2)       Aslan/Pachic Islander     1 (3.2)       Caucasian/White     2 4 (77.4)       Latino/Hispanic     2 (6.5)       Other     1 (3.2)       Kinden American/Black     2 (6.5)       Itwo or more races     2 (6.5)       S10,000 to \$19,999     1 (3.2)       S20,000 to \$39,999     1 (3.2)       S5,000 to race     1 (6.1)       Elocation level     1       College degree     10 (32.3)       Professional or graduate school experience     1 (6.1)       Vocational School or some college     2 (6.5)       Relationship status     1       Marited/partnered     2 (6.6%)       Divocred/sparated     3 (9.7%)       Single/never marited     3 (9.7%)       Relationship to patent     1       Farent     5 (16.1)       Sposse/partner     1 (6.1)       Ves constanty since diagno	Race/ethnicity		
Asian/Pacific Islander     1 (3.2)       Caucasian/White     24 (77.4)       Latino/Hispanic     2 (6.5)       Other     1 (3.2)       Two or more races     2 (6.5)       Income	African American/Black		1 (3.2)
Caucasian/White     24 (77.4)       Lating/Hispanic     2 (6.5)       Other     1 (3.2)       Two or more races     2 (6.5)       Income     1 (3.2)       \$20000 to \$39,999     1 (3.2)       \$20000 to \$39,999     1 (3.2)       \$5,000 to \$74,999     5 (16.1)       \$5,000 to \$74,999     5 (16.1)       \$5,000 to \$74,999     5 (16.1)       \$5,000 to \$74,999     1 (3.2)       ZOBOD or more     18 (58.1)       Prefer not to answer     5 (16.1)       College degree     10 (32.3)       Professional or graduate school experience     19 (61.3)       Vocational school or some college     2 (6.5)       Relationship status	Asian/Pacific Islander		1 (3.2)
Latino/Hispanic     2 (6.5)       Other     1 (3.2)       Two or more races     2 (6.5)       Income     1 (3.2)       S10,000 to \$19,999     1 (3.2)       S20,000 to \$39,999     1 (3.2)       S40,000 to \$74,999     5 (16.1)       S50,000 to \$39,999     1 (3.2)       S75,000 or more     18 (58.1)       Prefer not to answer     5 (16.1)       Education level	Caucasian/White		24 (77.4)
Other     1 (3.2)       Two or more races     2 (6.5)       Income     1 (3.2)       \$10,000 to \$19,999     1 (3.2)       \$20,000 to \$39,999     1 (3.2)       \$5,000 to \$9,999     1 (3.2)       \$5,000 or more     18 (58.1)       Prefer not to answer     5 (16.1)       Education level     10 (32.3)       College degree     10 (32.3)       Professional or graduate school experience     19 (61.3)       Vocational school or some college     2 (6.5)       Relationship status     10 (32.3)       Divorced/separated     3 (9.7%)       Single/never maried     3 (9.7%)       Relationship to patient     19 (61.3)       Child     6 (19.4)       Yes constantly since diagnosis     2 (11.4)       Yes constantly since diagnosis     2 (12.7)       Yes- and of since diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     18 (58.1)	Latino/Hispanic		2 (6.5)
Two or more races     2 (6.5)       Income     1 (3.2)       \$10,000 to \$19,999     1 (3.2)       \$20,000 to \$74,999     5 (16.1)       \$5,000 to \$79,999     1 (3.2)       \$75,000 or more     18 (58.1)       Preferent to answer     5 (16.1)       Education level	Other		1 (3.2)
Income     510,000 to \$19,999     1 (3.2)       \$20,000 to \$39,999     1 (3.2)       \$20,000 to \$74,999     5 (16.1)       \$5,000 to \$9,999     1 (3.2)       \$75,000 or more     18 (58.1)       Prefer not to answer     5 (16.1)       Education level     10 (32.3)       Professional or graduate school experience     19 (61.3)       Vocational school or some college     2 (6.5)       Relationship status     75 (16.1)       Married/partnered     25 (80.6%)       Divorced/separated     3 (9.7%)       Single/never married     3 (9.7%)       Single/never married     3 (9.7%)       Single/never married     3 (9.7%)       Solding     5 (16.1)       Spouse/partner     19 (61.3)       College degree     22 (71)       Yes—constantly since diagnosis     6 (19.4)       Yes—constantly since diagnosis     6 (19.4)       Yes_soloped before but currently am     3 (9.7)       Live with cancer patient     1 (3.2)       Ves, all of the time     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1) <td>Two or more races</td> <td></td> <td>2 (6.5)</td>	Two or more races		2 (6.5)
\$10,000 to \$19,999     1 (3.2)       \$20,000 to \$39,999     1 (3.2)       \$40,000 to \$74,999     5 (16.1)       \$5,000 to \$9,999     1 (3.2)       \$75,000 or more     18 (58.1)       Prefer not to answer     5 (16.1)       Education level	Income		
520,000 to \$39,999     1 (3.2)       \$50,000 to \$74,999     5 (16.1)       \$5,000 to \$79,999     1 (3.2)       \$75,000 or more     18 (58.1)       Prefer not to answer     5 (16.1)       Education level     6       College degree     10 (32.3)       Professional or graduate school experience     19 (61.3)       Vocational school or some college     2 (6.5)       Relationship status     7       Married/partnered     25 (80.6%)       Divorced/separated     3 (9.7%)       Single/never married     3 (9.7%)       Relationship status     7       Parent     5 (16.1)       Spouse/partner     19 (61.3)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care     7       Yes—constantly since diagnosis     22 (71)       Yes—onstantly since diagnosis     22 (71)       Yes—onstantly since diagnosis     5 (16.1)       No     8 (25.8)       Patient Cancer type     1       Brain     2 (6.5)       Breast     3 (9.	\$10.000 to \$19.999		1 (3.2)
\$40,000 to \$74,999     \$1(1.1)       \$50,000 to \$9,999     1(3.2)       \$75,000 or more     18 (58.1)       Prefer not to answer     \$1(6.1)       Education level     (0132.3)       Professional or graduate school experience     19 (61.3)       Vocational school or some college     26 (5)       Relationship status     (119)       Married/partnered     25 (80.6%)       Divorced/separated     3 (9.7%)       Relationship to patient     (129.4)       Parent     \$1(6.1)       Spouse/partner     19 (61.3)       College degree     10 (32.3)       Professional or graduate school experience     19 (61.3)       Single/never married     3 (9.7%)       Relationship to patient     5 (16.1)       Spouse/partner     19 (61.3)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care     22 (71)       Yes—constantly since diagnosis     22 (71)       Yes_stopped before but currently am     3 (9.7)       Lew with carcer patient     16 (5.1)       Yes, all of the time <td>\$20.000 to \$39.999</td> <td></td> <td>1 (3.2)</td>	\$20.000 to \$39.999		1 (3.2)
55,000 to 59,999     1 (3.2)       575,000 or more     18 (58.1)       Prefer not to answer     5 (16.1)       Education level	\$40.000 to \$74.999		5 (16.1)
575,000 or more     18 (58.1)       Prefer not to answer     5 (16.1)       Education level     College degree     10 (32.3)       Professional or graduate school experience     19 (61.3)     Vocational school or some college     2 (6.5)       Relationship status     Married/partnered     25 (80.6%)     Divorced/separated     3 (9.7%)       Single/never married     25 (80.6%)     Divorced/separated     3 (9.7%)       Relationship to patient     -     -       Parent     5 (16.1)     -       Spouse/partner     19 (61.3)     -       Child     6 (19.4)     -       Stolling     13 (3.2)     -       Currently providing care     -     -       Yes—constantly since diagnosis     22 (71)     -       Yes—on and off since diagnosis     2 (71)     -       Yes_sonce higher initial diagnosis     5 (16.1)     -       Ves     all of the time     18 (58.1)       Yes, since higher initial diagnosis     5 (16.1)     -       No     8 (25.8)     -       Patient cancer type     -	\$5.000 to \$9.999		1 (3.2)
Prefer not to answer     5 (16.1)       Education level     (0 (32.3)       College degree     10 (32.3)       Professional or graduate school experience     19 (61.3)       Vocational school or some college     2 (6.5)       Relationship status     (3 (9.7%))       Married/partnered     25 (80.6%)       Divorced/separated     3 (9.7%)       Single/never married     3 (9.7%)       Relationship to patient     (6 (19.4))       Parent     5 (16.1)       Spouse/partner     19 (61.3)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care     Yes-constantly since diagnosis       Yes-on and off since diagnosis     6 (19.4)       Yes-aloped before but currently am     3 (9.7)       Live with cancer patient     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     Brain       Brain     2 (65.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esophagus     1 (3.2) <td>\$75.000 or more</td> <td></td> <td>18 (58.1)</td>	\$75.000 or more		18 (58.1)
Education level     1 (2009)       College degree     10 (32.3)       Professional or graduate school experience     19 (61.3)       Vocational school or some college     2 (6.5)       Relationship status     3 (9.7%)       Married/partnered     25 (80.6%)       Divorced/separated     3 (9.7%)       Single/never married     3 (9.7%)       Relationship to patient     19 (61.3)       Parent     5 (16.1)       Spouse/partner     19 (61.3)       Currently providing care     22 (71)       Yes-constantly since diagnosis     6 (19.4)       Yes-constantly since diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     18 (26.1)       Brain     2 (6.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esphague     1 (3.2)       Ovarian     3 (9	Prefer not to answer		5 (16.1)
College degree     10 (32.3)       Professional or graduate school experience     19 (61.3)       Vocational school or some college     2 (6.5)       Relationship status     25 (80.6%)       Divorced/separated     3 (9.7%)       Single/never married     3 (9.7%)       Relationship to patient     7       Parent     5 (16.1)       Spouse/partner     19 (61.3)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care     7       Yes-constantly since diagnosis     22 (71)       Yes-atoped before but currently am     3 (9.7)       Live with cancer patient     10 (2.2)       Ves, all of the time     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     8       Brain     2 (6.5)       Breast     3 (9.7)       Low on conclus     1 (3.2)       Ovarian     3 (9.7)       Expoped before but currently am     2 (6.5)       Breast     3 (9.7)       Low on conclus	Education level		
Interpretational or graduate school experience     19 (61.3)       Vocational school or some college     2 (6.5)       Relationship status	College degree		10 (32,3)
10 (15)     10 (15)       Protectional school or some college     2 (6.5)       Relationship status     3 (9.7%)       Married/partnered     3 (9.7%)       Single/never married     3 (9.7%)       Relationship to patient     9 (6.1.3)       Parent     5 (16.1)       Spouse/partner     19 (61.3)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care     22 (71)       Yesconstantly since diagnosis     6 (19.4)       Yesconstantly since diagnosis     6 (19.4)       Yesconstantly since diagnosis     6 (19.4)       Yes-supped before but currently am     3 (9.7)       Live with cancer patient     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     1       Brain     2 (6.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esophagus     1 (3.2)       Luekemia/non-Hodgkin's lymphoma     2 (6.5)       Lung or bronchus     1 (3.2)	Professional or graduate school experience		19 (61 3)
Relationship status     2 (80.6%)       Married/partnered     25 (80.6%)       Divorced/separated     3 (9.7%)       Single/never married     3 (9.7%)       Relationship to patient     7       Parent     5 (16.1)       Spouse/partner     19 (61.3)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care     7       Yes-constantly since diagnosis     22 (71)       Yes-constantly since diagnosis     6 (19.4)       Yes-constantly since diagnosis     6 (19.4)       Yes-and off since diagnosis     6 (19.4)       Yes-and off since diagnosis     6 (19.4)       Yes-stopped before but currently am     3 (9.7)       Live with cancer patient     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     1       Brain     2 (6.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Ovarian     3 (9.7)       Parceras     2 (6.5)       Prostate	Vocational school or some college		2 (6.5)
Married/partnered     25 (80.6%)       Divorced/separated     3 (9.7%)       Single/never married     3 (9.7%)       Relationship to patient	Relationship status		
Interseptence     10       Divorced/separated     3 (9.7%)       Single/never married     3 (9.7%)       Relationship to patient     19       Parent     5 (16.1)       Spouse/partner     19 (61.3)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care     22 (71)       Yes—constantly since diagnosis     22 (71)       Yes—on and off since diagnosis     6 (19.4)       Yes—stopped before but currently am     3 (9.7)       Live with cancer patient     10       Yes, all of the time     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     2 (6.5)       Brain     2 (6.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esophagus     1 (3.2)       Lukemia/non-Hodgkin's tymphoma     2 (6.5)       Lung or bronchus     1 (3.2)       Qvarian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)  <	Married/partnered		25 (80.6%)
Introduction     1 (1115)       Single/never married     3 (9.7%)       Relationship to patient     5 (16.1)       Spouse/partner     19 (61.3)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care	Divorced/separated		3 (9.7%)
Description     2 (6170)       Parent     5 (16.1)       Spouse/partner     19 (61.3)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care	Single/never married		3 (9.7%)
Parent     5 (16.1)       Spouse/partner     19 (61.3)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care	Relationship to patient		
Spouse/partner     19 (61.3)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care     22 (71)       Yes—constantly since diagnosis     22 (71)       Yes—constantly since diagnosis     6 (19.4)       Yes—and off since diagnosis     6 (19.4)       Yes—and off since diagnosis     5 (16.1)       Ive with cancer patient     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     10       Brain     2 (6.5)       Breast     3 (9.7)       Color or rectum     4 (12.9)       Esophagus     1 (3.2)       Userian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Skin melanoma     1 (3.2)       <	Parent		5 (16 1)
Dependent     13 (213)       Child     6 (19.4)       Sibling     1 (3.2)       Currently providing care     22 (71)       Yes—constantly since diagnosis     22 (71)       Yes—on and off since diagnosis     6 (19.4)       Yes—stopped before but currently am     3 (9.7)       Live with cancer patient     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     8       Brain     2 (6.5)       Breast     3 (9.7)       Color or rectum     4 (12.9)       Esophagus     1 (3.2)       Leukemia/non-Hodgkin's lymphoma     2 (6.5)       Lung or bronchus     1 (3.2)       Ovarian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Uterine     3 (9.7)       Potate     1 (3.2)       Warian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Vitrine     3 (9.7)       Other     4 (12.9)	Spouse/partner		19 (61 3)
Sibling     1 (3.2)       Currently providing care     22 (71)       Yes—constantly since diagnosis     22 (71)       Yes—constantly since diagnosis     6 (19.4)       Yes—and off since diagnosis     6 (19.4)       Yes—stopped before but currently am     3 (9.7)       Live with cancer patient     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     8       Brain     2 (6.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esophagus     1 (3.2)       Leukemia/non-Hodgkin's lymphoma     2 (6.5)       Lung or bronchus     1 (3.2)       Ovarian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Skin melanoma     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)       More than one	Child		6 (19 4)
Currently providing care     22 (71)       Yes—constantly since diagnosis     22 (71)       Yes—constantly since diagnosis     6 (19.4)       Yes—on and off since diagnosis     6 (19.4)       Yes—on and off since diagnosis     6 (19.4)       Yes—stopped before but currently am     3 (9.7)       Live with cancer patient     18 (58.1)       Yes, all of the time     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     8       Brain     2 (6.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esophagus     1 (3.2)       Leukemia/non-Hodgkin's lymphoma     2 (6.5)       Lung or bronchus     1 (3.2)       Ovarian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Skin melanoma     1 (3.2)       Uterine     3 (9.7)       Ower than one site     4 (12.9)	Sibling		1 (3.2)
Yes-constantly since diagnosis     22 (71)       Yes-constantly since diagnosis     6 (19.4)       Yes-on and off since diagnosis     6 (19.4)       Yes-stopped before but currently am     3 (9.7)       Live with cancer patient     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     8       Brain     2 (6.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esophagus     1 (3.2)       Luemia/non-Hodgkin's lymphoma     2 (6.5)       Prostate     1 (3.2)       Uterine     3 (9.7)       Ovarian     3 (9.7)       Patiente     1 (3.2)       Uterine     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Skin melanoma     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)	Currently providing care		
The constant parts and off since diagnosis     Image: Constant parts       Yes—on and off since diagnosis     6 (19.4)       Yes—stopped before but currently am     3 (9.7)       Live with cancer patient     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     18       Brain     2 (6.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esophagus     1 (3.2)       Luemia/non-Hodgkin's lymphoma     2 (6.5)       Lung or bronchus     1 (3.2)       Ovarian     3 (9.7)       Pastet     2 (6.5)       Prostate     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)	Yes—constantly since diagnosis		22 (71)
Yes     Strate angle before but currently am     3 (9.7)       Live with cancer patient     18 (58.1)       Yes, all of the time     18 (58.1)       Yes, since his/her initial diagnosis     5 (16.1)       No     8 (25.8)       Patient cancer type     10 (1.7)       Brain     2 (6.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esophagus     1 (3.2)       Leukemia/non-Hodgkin's lymphoma     2 (6.5)       Lung or bronchus     1 (3.2)       Ovarian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)	Yes—on and off since diagnosis		6 (19,4)
Live with cancer patient18 (58.1)Yes, all of the time18 (58.1)Yes, since his/her initial diagnosis5 (16.1)No8 (25.8)Patient cancer type2 (6.5)Breast3 (9.7)Colon or rectum4 (12.9)Esophagus1 (3.2)Leukemia/non-Hodgkin's lymphoma2 (6.5)Lung or bronchus1 (3.2)Ovarian3 (9.7)Pancreas2 (6.5)Prostate1 (3.2)Uterine3 (9.7)Other4 (12.9)More than one site4 (12.9)	Yes—stopped before but currently am		3 (9.7)
Yes, all of the time18 (58.1)Yes, since his/her initial diagnosis5 (16.1)No8 (25.8)Patient cancer typeBrain2 (6.5)Breast3 (9.7)Colon or rectum4 (12.9)Esophagus1 (3.2)Leukemia/non-Hodgkin's lymphoma2 (6.5)Lung or bronchus1 (3.2)Ovarian3 (9.7)Pancreas2 (6.5)Prostate1 (3.2)Skin melanoma1 (3.2)Uterine3 (9.7)Other4 (12.9)	live with cancer natient		
Yes, since his/her initial diagnosis5 (16.1)No8 (25.8)Patient cancer typeBrain2 (6.5)Breast3 (9.7)Colon or rectum4 (12.9)Esophagus1 (3.2)Leukemia/non-Hodgkin's lymphoma2 (6.5)Lung or bronchus1 (3.2)Ovarian3 (9.7)Pancreas2 (6.5)Prostate1 (3.2)Uterine3 (9.7)Other4 (12.9)	Yes, all of the time		18 (58.1)
No     8 (25.8)       Patient cancer type	Yes, since his/her initial diagnosis		5 (16.1)
Patient cancer type     2 (6.5)       Brain     2 (6.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esophagus     1 (3.2)       Leukemia/non-Hodgkin's lymphoma     2 (6.5)       Lung or bronchus     1 (3.2)       Ovarian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Skin melanoma     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)	No		8 (25.8)
Brain     2 (6.5)       Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esophagus     1 (3.2)       Leukemia/non-Hodgkin's lymphoma     2 (6.5)       Lung or bronchus     1 (3.2)       Ovarian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)       More than one site     4 (12.9)	Patient cancer type		
Breast     3 (9.7)       Colon or rectum     4 (12.9)       Esophagus     1 (3.2)       Leukemia/non-Hodgkin's lymphoma     2 (6.5)       Lung or bronchus     1 (3.2)       Ovarian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Skin melanoma     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)       More than one site     4 (12.9)	Brain		2 (6.5)
Colon or rectum     4 (12.9)       Esophagus     1 (3.2)       Leukemia/non-Hodgkin's lymphoma     2 (6.5)       Lung or bronchus     1 (3.2)       Ovarian     3 (9.7)       Pancreas     2 (6.5)       In (3.2)     2 (6.5)       Uterine     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)       More than one site     4 (12.9)	Breast		3 (9.7)
Esophagus1 (3.2)Leukemia/non-Hodgkin's lymphoma2 (6.5)Lung or bronchus1 (3.2)Ovarian3 (9.7)Pancreas2 (6.5)Prostate1 (3.2)Skin melanoma1 (3.2)Uterine3 (9.7)Other4 (12.9)More than one site4 (12.9)	Colon or rectum		4 (12.9)
Leukemia/non-Hodgkin's lymphoma2 (6.5)Lung or bronchus1 (3.2)Ovarian3 (9.7)Pancreas2 (6.5)Prostate1 (3.2)Skin melanoma1 (3.2)Uterine3 (9.7)Other4 (12.9)More than one site4 (12.9)	Esophagus		1 (3.2)
Lung or bronchus     1 (3.2)       Ovarian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Skin melanoma     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)       More than one site     4 (12.9)	l eukemia/non-Hodgkin's lymphoma		2 (6.5)
Ovarian     3 (9.7)       Pancreas     2 (6.5)       Prostate     1 (3.2)       Skin melanoma     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)       More than one site     4 (12.9)	Lung or bronchus		1 (3.2)
Pancreas     2 (6.5)       Prostate     1 (3.2)       Skin melanoma     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)       More than one site     4 (12.9)	Ovarian		3 (9.7)
Prostate     1 (3.2)       Skin melanoma     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)       More than one site     4 (12.9)	Pancreas		2 (6.5)
Skin melanoma     1 (3.2)       Uterine     3 (9.7)       Other     4 (12.9)       More than one site     4 (12.9)	Prostate		1 (3.2)
Uterine     3 (9.7)       Other     4 (12.9)       More than one site     4 (12.9)	Skin melanoma		1 (3.2)
Other     4 (12.9)       More than one site     4 (12.9)	Uterine		3 (9.7)
More than one site 4 (12.9)	Other		4 (12.9)
	More than one site		4 (12.9)

Table 1   Continued		
Characteristic	Mean ( <i>SD</i> )	Frequency (%)
Patient cancer stage		
Stage 1		3 (9.7)
Stage 2		3 (9.7)
Stage 3		4 (12.9)
Stage 4		16 (51.6)
Unstaged		3 (9.7)
Doesn't know		2 (6.5)



#### Fig 1 | Trend data.

indicate a decrease over time, treatment completers had lower baseline CRA scores and the differences for completers was a mean increase.

#### DISCUSSION

This pilot trial of ERT-C provides strong support for the feasibility and acceptability of this approach to addressing distress in ICs, as well as the potential for ERT-C to lead to improvements in PNT in this population. ERT-C was well tolerated; only 31% of enrolled participants did not complete all ERT-C sessions and 37.5% of participants did not complete our T2 assessment. These rates are low compared to other investigations of interventions for ICs with similar doses (e.g., attrition rates between 57% and 75% reported [64]), and comparable to other studies conducted at the same institution with patients with advanced cancer and their ICs [65]. The success here in recruiting and retaining ICs in this in-person intervention is likely due, in part, to efforts made by the treatment team to schedule sessions at times that were convenient for ICs, often concurrent when their loved ones' medical visits. These rates may also reflect the encouraging data derived from the in-depth interviews for the feasibility and acceptability of ERT-C. Not only did ICs find the material engaging and the in-session exercises beneficial, but too, recognized the benefits of completing homework assignments and practicing ERT-C skills in between sessions. Discussion of homework assignments has been inconsistently reported in previous similar trials with ICs [66-68], and these data serve as promising evidence for ICs' engagement with ERT-C exercises between sessions, which likely contributed to the improvements in PNT reported above. In a highly burdened population that historically underutilizes psychosocial services due to the many demands of caregiving, participants' reported desire for booster sessions and preference for in-person versus webbased delivery are indeed notable. Through its focus on the function of emotions and ICs' proactively

Table 2   Effect of ERT-C on I	measure and subscale scores				
Measure	Pre-ERT-C, <i>n</i> = 31 Mean (95% CI)	Post-ERT-C, <i>n</i> = 20 Mean (95% Cl)	Diff, <i>n</i> = 20 Mean (95% CI)	Hedge's <i>g</i>	<i>p</i> -value
Depression and anxiety me	easures				
HADS total	18.87 (16.51, 21.24)	14.74 (12.28, 17.19)	-4.58 (-7.62, -1.54)	0.65	.009
HADS anxiety	11.55 (10.36, 12.74)	9.37 (7.98, 10.76)	-2.74 (-4.40, -1.08)	0.66	.005
HADS depression	7.32 (5.79, 8.85)	5.37 (4.02, 6.72)	-1.84 (-3.53, -0.16)	0.49	.046
Perseverative negative thin	nking measures				
Rumination (Brooding) Scale	45.74 (41.65, 49.83)	42.68 (39.58, 45.79)	-3.89 (-6.91, -0.88)	0.36	.006
Penn State Worry Questionnaire	54.77 (49.95, 59.6)	48.68 (43.88, 53.49)	-8.79 (-12.85, -4.73)	0.47	<.001
Emotion regulation measur	res				
Difficulties in emotion regulation	81.94 (74.32, 89.55)	68.37 (61.17, 75.57)	-13.42 (-20.19, -6.65)	0.68	.001
Five Facet Mindfulness Questionnaire	126.87 (121.0, 132.7)	143.95 (134.7, 153.2)	17.42 (10.78, 24.06)	-0.92	<.001
Caregiver measure					
Caregiver Reaction Assessment <sup>a</sup>	79.65 (76.4, 82.89)	78.35 (75.08, 81.62)	1.45 (-3.00, 5.90)	0.15	.531
EDTC Emotion Degulation Thoran	for Concor Coroginary UADCHash	ital Anviaty and Depression Coale			

*ERT-C* Emotion Regulation Therapy for Cancer Caregivers; *HADS* Hospital Anxiety and Depression Scale.

<sup>a</sup>Pre-ERT-C CRA scores were significantly higher for participants who did not complete post-ERT-C assessments; thus, the cross-sectional means appear to indicate a decrease, whereas the change score for completers is an increase.

taking actions consistent with their values, ERT adapted for the unique setting of cancer caregiving may feel more consonant with ICs' experiences and hence may reflect a more meaningful approach than traditional CBTs for this uniquely burdened population. Importantly, despite the success reported here in recruiting and retaining ICs, these rates also highlight the continued challenges of maintaining IC in in-person psychotherapy and engaging them after they have completed sessions. In future studies, efforts will be needed to understand the specific factors that contribute to attrition at various time points and identify strategies to maintain ICs in trials once active treatment has been completed.

This trial of ERT-C provides preliminary evidence for ERT-C in addressing multiple domains of IC well-being. Specifically, ERT-C evidenced meaningful reductions in depressive and anxious symptomatology, PNT, and emotion regulation deficits. To date, interventions have been generally unsuccessful in mitigating the anxiety and depression symptomatology that is so common among ICs, which may be due largely in part to their not addressing the core mechanisms underlying these symptom clusters. Indeed, our meta-analytic results for CBTs for ICs found only small effect sizes for reductions in anxiety and depression, which disappeared when RCTs were evaluated alone [29]. Here, ERT-C evidenced notably larger and significant reductions in anxiety and depression as well as worry and rumination (i.e., medium effect sizes) and improved participants' emotion regulation skills (i.e., large effect sizes). These results in the context of a single-arm design provide preliminary evidence of ERT-C as a potentially more efficacious intervention than previous CBTs for ICs, and a comparable one to CBTs delivered to individuals seeking treatment for mood and anxiety disorders [27, 28]. The caregiving experience is marked by chronic uncertainty and hence, a critical task for ICs is to manage this uncertainty. Improvement in these emotion regulation skills likely allowed participants to manage the day-to-day challenges and uncertainties with less distress and related elevations in anxiety and depression symptoms.

ERT-C did not evidence significant reductions in IC burden. Although perhaps surprising against the backdrop of our other positive findings, the attenuated impact of ERT-C on burden is understandable when we consider the various determinants of burden and the range of variables comprised in the CRA. Burden reflects a "multidimensional biopsychosocial reaction resulting from an imbalance of care demands relative to caregivers' personal time, social roles, physical and emotional states, financial resources, and formal care resources given the other multiple roles they fulfill" [69]. In addition to addressing the emotional components of burden (e.g., anxiety, depression), the CRA assesses social support, finances, schedule, and physical health. Although it is possible that enhanced emotion regulation skills over long periods may contribute to improvements in some of these areas, we would not anticipate an impact on all of the unique domains of burden within 2 months of completing of ERT-C. Additionally, the majority of our participants were caring for patients with advanced (51.6% Stage 4, 12.9% Stage 3) cancers and were in spousal

relationships to patients, factors which likely contributed to the burden of care documented here [70-72]. Moreover, in the caregiving literature, the "concurrence of meaning and suffering" is often discussed [73], in that despite increased burden (e.g., schedule disruptions, financial toxicity, ICs' own medical problems), the possibility of greater emotional well-being may be attainable. Our data serve as evidence of this experience.

#### Limitations

Several limitations of this investigation must be acknowledged. First, this study is limited by its sample size and noncontrolled design. Second, our participants were primarily non-Hispanic Whites and of higher socioeconomic status, thereby restricting the generalizability of findings. Our participants were also overwhelmingly female, though this sample composition is not significantly different from other trials of ICs across the USA. Nonetheless, future trials of ERT-C may wish to oversample male ICs to examine whether gender moderates treatment outcomes. Third, participants who dropped out of ERT-C reported significantly higher IC burden at baseline than those who completed all ERT-C sessions. As such, our participant sample likely did not fully capture the range and complexity of caregiving experiences. Fourth, only 10 participants engaged in in-depth semistructured interviews about their experiences in ERT-C. As these 10 participants were also treatment completers, this small sample failed to capture meaningful data regarding causes of attrition and the range of experiences in the trial. Finally, we relied on participant report of patient medical characteristics instead of medical chart review to determine eligibility (i.e., current IC to a patient enrolled at MSK). Although exploration of patient's disease site and stage, treatment type, and prognosis were not variables of interest in the current investigation, such data would have allowed for the determination of potential impact of stage in caregiving trajectory on outcomes in ERT-C.

#### **Future Directions**

Further research is needed to establish the efficacy of ERT-C using a RCT design comparing ERT-C to either standard care or a comparable supportive care. Toward this end, we are currently conducting a RCT of ERT-C delivered to lung and colorectal cancer ICs in Denmark (Clinical Trial Registration Number NCT02322905), and plan to conduct a correlate study here in the USA with ICs of patients with all sites and stages of cancer. Future studies should include longer follow-up periods and larger sample sizes which will allow for richly assessing psychological-as well as biological and physiological-mechanisms underlying the changes resulting from ERT-C. Such studies should also systematically examine the contribution of caregiver burden to study enrollment and retention. Additionally, once the efficacy of ERT-C has been established in the context of a RCT, an important future direction will be to evaluate the delivery of ERT-C via telehealth modalities to facilitate delivery to a larger and more diverse sample of ICs.

Acknowledgments: The authors would like to thank Eliabeth Schofield, MPH, and Ashley Tigershtrom, BA, for their assistance in the preparation of this manuscript. This work was supported by a grant from the TJ. Martell Foundation to Dr. A.J. Applebaum.

Author Contributions: All authors listed have made substantial, direct, and intellectual contributions to this work and approved it for publication.

#### Compliance with Ethical Standards

Conflict of Interest: No authors have any conflicts of interest to report.

Ethical Approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Study procedures were reviewed by the Memorial Sloan Kettering Institutional Review Board (approval number 15-219) and the Clinical Trial Registration Number for this study is NCT02697357. This article does not contain any studies with animals performed by any of the authors.

**Informed Consent:** Informed consent was obtained from all individual participants before enrollment in the study.

#### References

- AARP, N.A.f.C. Cancer Caregiving in the U.S. An intense, episodic, and challenging care experience. Research report 2016. Available at http://www.caregiving.org/wp-content/uploads/2016/06/Cancer CaregivingReport\_FINAL\_june-17–2016. Accessibility verified March 10, 2018.
- Reinhard SC, Feinberg LS, Choula R, Houser A. Valuing the invaluable: 2015 update. Washington, DC: AARP, Public Policy Institute; 2015.
- Boyle D, Blodgett L, Gnesdiloff S, et al. Caregiver quality of life after autologous bone marrow transplantation. *Cancer Nurs.* 2000;23(3):193–203.
- Kuijer RG, Buunk BP, Ybema JF, Wobbes T. The relation between perceived inequity, marital satisfaction and emotions among couples facing cancer. Br J Soc Psychol. 2002;41(pt 1):39–56.
- Askari A, Madgaonkar S, Rowell, R. Current psycho-pathological issues among partners of cancer patients. J Psychosoc Res. 2012;7(1):77.
- Braun M, Mikulincer M, Rydall A, Walsh A, Rodin G. Hidden morbidity in cancer: spouse caregivers. J Clin Oncol. 2007;25(30):4829–4834.
- Clavarino AM, Lowe JB, Carmont SA, Balanda K. The needs of cancer patients and their families from rural and remote areas of Queensland. *Aust J Rural Health.* 2002;10(4):188–195.
- Cliff AM, MacDonagh RP. Psychosocial morbidity in prostate cancer: II. A comparison of patients and partners. *BJU Int.* 2000;86(7):834–839.
- Covinsky KE, Goldman L, Cook EF, et al. The impact of serious illness on patients' families. SUPPORT investigators. Study to understand prognoses and preferences for outcomes and risks of treatment. *JAMA*. 1994;272(23):1839–1844.
- Hudson PL, Thomas K, Trauer T, Remedios C, Clarke D. Psychological and social profile of family caregivers on commencement of palliative care. J Pain Symptom Manage. 2011;41(3):522–534.
- Kim Y, Shaffer KM, Carver CS, Cannady RS. Prevalence and predictors of depressive symptoms among cancer caregivers 5 years after the relative's cancer diagnosis. J Consult Clin Psychol. 2014;82(1):1–8.
- 12. Christakis NA, Allison PD. Mortality after the hospitalization of a spouse. *N Engl J Med.* 2006;354(7):719–730.
- Rohleder N, Marin TJ, Ma R, Miller GE. Biologic cost of caring for a cancer patient: dysregulation of pro- and anti-inflammatory signaling pathways. *J Clin Oncol.* 2009;27(18):2909–2915.
- Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. *PLoS Med.* 2008;5(4):e78.
- Mennin DS, Fresco DM, Ritter M, Heimberg RG. An open trial of emotion regulation therapy for generalized anxiety disorder and cooccurring depression. *Depress Anxiety*. 2015;32(8):614–623.
- Brosschot JF, Verkuil B, Thayer JF. Generalized unsafety theory of stress: unsafe environments and conditions, and the default stress response. *Int J Environ Res Public Health*. 2018;15(3):464–490.

- Gaugler JE, Eppinger A, King J, Sandberg T, Regine WF. Coping and its effects on cancer caregiving. *Support Care Cancer.* 2013;21(2):385–395.
- Mosher CE, Jaynes HA, Hanna N, Ostroff JS. Distressed family caregivers of lung cancer patients: an examination of psychosocial and practical challenges. *Support Care Cancer.* 2013;21(2):431–437.
- Walker RJ, Pomeroy EC. Depression or grief? The experience of caregivers of people with dementia. *Health Soc Work*. 1996;21(4):247–254.
- Etkin A, Schatzberg AF. Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. *Am J Psychiatry*. 2011;168(9):968–978.
- Joormann J, Dkane M, Gotlib IH. Adaptive and maladaptive components of rumination? Diagnostic specificity and relation to depressive biases. *Behav Ther.* 2006;37(3):269–280.
- 22. Mennin DS, Fresco DM, Heimberg RG, Ciesla J. Randomized control trial of Emotion Regulation Therapy for generalized anxiety disorder and comorbid depression. In M. Fraire, T. Ollendick (Chairs). Emotion regulation in anxiety 48 disorders across the lifespan: Comorbidity and treatment. 2012. Paper presented at the annual meeting of the Anxiety Disorders Association of America, Arlington, VA.
- Applebaum AJ, Farran CJ, Marziliano AM, Pasternak AR, Breitbart W. Preliminary study of themes of meaning and psychosocial service use among informal cancer caregivers. *Palliat Support Care*. 2014;12(2):139–148.
- Mitchell A, Pössel P. Repetitive negative thinking: the link between caregiver burden and depressive symptoms. Oncol Nurs Forum. 2017;44(2):210–216.
- Galfin JM, Watkins ER, Harlow T. Psychological distress and rumination in palliative care patients and their caregivers. J Palliat Med. 2010;13(11):1345–1348.
- Mosher CE, Champion VL, Hanna N, et al. Support service use and interest in support services among distressed family caregivers of lung cancer patients. *Psychooncology*. 2013;22(7):1549–1556.
- Hans E, Hiller W. Effectiveness of and dropout from outpatient cognitive behavioral therapy for adult unipolar depression: a meta-analysis of nonrandomized effectiveness studies. J Consult Clin Psychol. 2013;81(1):75–88.
- Hofmann SG, Wu JQ, Boettcher H. Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: a meta-analysis. J Consult Clin Psychol. 2014;82(3):375–391.
- 29. O'Toole MS, Zachariae R, Renna ME, Mennin DS, Applebaum A. Cognitive behavioral therapies for informal caregivers of patients with cancer and cancer survivors: a systematic review and meta-analysis. *Psychooncology*. 2017;26(4):428–437.
- Fresco DM, Mennin DS, Heimberg RG, Ritter M. Emotion regulation therapy for generalized anxiety disorder. *Cogn Behav Pract*. 2013;20(3):282–300.
  Greenberg LS. Integrating an emotion-focused approach to treatment
- into psychotherapy integration. *J Psychother Integr.* 2002;12(2):154. 32. Mennin DS, Fresco D. Emotion regulation therapy. In: Gross JJ, ed. Handbook
- of emotion regulation. New York: Guilford Press; 2013:469–490.
- Renna ME, Quintero JM, Fresco DM, Mennin DS. Emotion regulation therapy: a mechanism-targeted treatment for disorders of distress. *Front Psychol.* 2017;8:98.
- Fresco DM, Roy AK, Adelsberg S, et al. Distinct functional connectivities predict clinical response with emotion regulation therapy. Front Hum Neurosci. 2017;11:86.
- Renna ME, Quintero JM, Soffer A, et al. A pilot study of emotion regulation therapy for generalized anxiety and depression: findings from a diverse sample of young adults. *Behav Ther.* 2018;49(3):403–418.
- Applebaum AJ, Buda KL, Schofield E, et al. Exploring the cancer caregiver's journey through web-based meaning-centered psychotherapy. *Psychooncology*, 2018;27(3):847–856.
- 37. Dionne-Odom JN, Azuero A, Lyons KD, et al. Benefits of early versus delayed palliative care to informal family caregivers of patients with advanced cancer: outcomes from the ENABLE III randomized controlled trial. J Clin Oncol. 2015;33(13):1446–1452.
- Longacre ML, Applebaum AJ, Buzaglo JS, et al. Reducing informal caregiver burden in cancer: evidence-based programs in practice. *Transl Behav Med.* 2018;8(2):145–155.
- Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. *Cancer.* 1998;82(10):1904–1908.
- Treynor W, Gonzalez R, Nolen-Hoeksema S. Rumination reconsidered: a psychometric analysis. *Cognit Ther Res.* 2003;27(3):247–259.
- Kertz SJ, Lee J, Björgvinsson T. Psychometric properties of abbreviated and ultra-brief versions of the Penn State Worry Questionnaire. *Psychol Assess.* 2014;26(4):1146–1154.
- Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. *Field Methods*. 2006;18(1):59–82.
- Caserta M, Lund D, Utz R, de Vries B. Stress-related growth among the recently bereaved. Aging Ment Health. 2009;13(3):463–476.
- Holland JC, Andersen B, Breitbart WS, et al. Distress management. J Natl Compr Canc Netw. 2010;8(4):448–485.
- 45. Grassi L, Sabato S, Rossi E, Marmai L, Biancosino B. Affective syndromes and their screening in cancer patients with early and stable disease: Italian ICD-10 data and performance of the distress thermometer from

the Southern European psycho-oncology study (SEPOS). J Affect Disord. 2009;114(1–3):193–199.

- Jacobsen PB, Donovan KA, Trask PC, et al. Screening for psychologic distress in ambulatory cancer patients. *Cancer*. 2005;103(7):1494–1502.
- Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. *Behav Res Ther.* 1990;28(6):487–495.
- Given CW, Given B, Stommel M, Collins C, King S, Franklin S. The caregiver reaction assessment (CRA) for caregivers to persons with chronic physical and mental impairments. *Res Nurs Health.* 1992;15(4):271–283.
- Given B, Wyatt G, Given C, et al. Burden and depression among caregivers of patients with cancer at the end of life. *Oncol Nurs Forum.* 2004;31(6):1105–1117.
- McCorkle R, Yost LS, Jepson C, Malone D, Baird S, Lusk E. A cancer experience: relationship of patient psychosocial responses to care-giver burden over time. *Psychooncology*. 1993;2:21–32.
- Nijboer C, Triemstra M, Tempelaar R, Sanderman R, van den Bos GA. Measuring both negative and positive reactions to giving care to cancer patients: psychometric qualities of the caregiver reaction assessment (CRA). Soc Sci Med. 1999;48(9):1259–1269.
- Nijboer C, Tempelaar R, Triemstra M, van den Bos GA, Sanderman R. The role of social and psychologic resources in caregiving of cancer patients. *Cancer*. 2001;91(5):1029–1039.
- Snaith RP, Zigmond AS. The hospital anxiety and depression scale. Br Med J (Clin Res Ed). 1986;292(6596):344.
- Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the hospital anxiety and depression scale. An updated literature review. J Psychosom Res. 2002;52(2):69–77.
- Savard J, Laberge B, Gauthier JG, Ivers H, Bergeron MG. Evaluating anxiety and depression in HIV-infected patients. J Pers Assess. 1998;71(3):349–367.
- 56. Gratz KL, Roemer L. Multidimensional assessment of emotion regulation and dysregulation: development, factor structure, and initial validation of the difficulties in emotion regulation scale. J Psychopathol Behav Assess. 2004;26(1):41–54.
- Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. *Assessment*. 2006;13(1):27–45.
- Baer RA, Smith GT, Lykins E, et al. Construct validity of the five facet mindfulness questionnaire in meditating and nonmeditating samples. *Assessment*. 2008;15(3):329–342.
- 59. Hedges L, Olkin I. *Statistical method for meta-analysis*. San Diego, CA: Academic Press; 1985.
- 60. Bernard HR. Research methods in anthropology: qualitative and quantitative approaches. Lanham, MD: Rowman & Littlefield; 2017.
- Boyatzis RE. Transforming qualitative information: thematic analysis and code development. Thousand Oaks, CA: Sage; 1998.
- 62. Creswell JW, Inquiry Q: research design: choosing among five approaches. Thousand Oaks, CA: Sage; 2007.
- 63. Green J, Thorogood N. *Qualitative methods for health research*. Thousand Oaks, CA: Sage; Sage; 2013.
- Walsh K, Jones L, Tookman A, et al. Reducing emotional distress in people caring for patients receiving specialist palliative care. Randomised trial. Br J Psychiatry. 2007;190(2):142–147.
- 65. Applebaum AJ, Lichtenthal WG, Pessin HA, et al. Factors associated with attrition from a randomized controlled trial of meaning-centered group psychotherapy for patients with advanced cancer. *Psychooncology*. 2012;21(11):1195–1204.
- 66. Kuijer RG, Buunk BP, De Jong GM, Ybema JF, Sanderman R. Effects of a brief intervention program for patients with cancer and their partners on feelings of inequity, relationship quality and psychological distress. *Psychooncology*. 2004;13(5):321–334.
- Chambers SK, Girgis A, Occhipinti S, et al. A randomized trial comparing two low-intensity psychological interventions for distressed patients with cancer and their caregivers. *Oncol Nurs Forum.* 2014;41(4):E256–E266.
- Laudenslager ML, Simoneau TL, Kilbourn K, et al. A randomized control trial of a psychosocial intervention for caregivers of allogeneic hematopoietic stem cell transplant patients: effects on distress. *Bone Marrow Transplant*. 2015;50(8):1110–1118.
- Given CW, Given B, Azzouz F, Kozachik S, Stommel M. Predictors of pain and fatigue in the year following diagnosis among elderly cancer patients. J Pain Symptom Manage. 2001;21(6):456–466.
- Hackett J, Godfrey M, Bennett MI. Patient and caregiver perspectives on managing pain in advanced cancer: a qualitative longitudinal study. *Palliat Med.* 2016;30(8):711–719.
- Lima JC, Allen SM, Goldscheider F, Intrator O. Spousal caregiving in late midlife versus older ages: implications of work and family obligations. J Gerontol B Psychol Sci Soc Sci. 2008;63(4):S229–S238.
- Girgis A, Abernethy AP, Currow DC. Caring at the end of life: do cancer caregivers differ from other caregivers? *BMJ Support Palliat Care*. 2015;5(5):513–517.
- 73. Mantulak A, Nicholas DB. "We're not going to say it's suffering; we're going to say it's an experience": the lived experience of maternal caregivers in pediatric kidney transplantation. Soc Work Health Care. 2016;55(8):580–594.